Get the Daily Brief
Latest Biotech News
M&A – immunology platform buyout
Eli Lilly moved further into precision immunology by signing to acquire Merida Biosciences in a deal valued at up to $2.875 billion. Merida’s approach centers on selectively targeting and...
Clinical science – innate immune cells for better flu vaccines
New immunology research published in Nature Immunology identifies a lung-resident, monocyte-derived population that supports durable CD8+ T cell memory after influenza infection. The study...
Drug development – next-gen gene activation tool
Researchers reported a new gene-activation approach designed to work inside the body, aiming to overcome a key limitation of CRISPR-based tuning: delivery. The work describes a gene-activation...
Oncology pipeline & translational evidence – execution in trials
A Tufts Center for the Study of Drug Development analysis warns that sponsors and CROs are identifying clinical trial risks but failing to execute coordinated corrective action—an issue the...
Company IPO filing – immunology drug development
Electra Therapeutics filed for an IPO to fund development of an immunology and oncology pipeline anchored by ipsoprubart (formerly ELA026) for secondary hemophagocytic lymphohistiocytosis (sHLH)....
Molecular tools – targeted protein degradation via DUPAC ADCs
Dualitybio and Genentech entered a collaboration and license agreement to develop next-generation antibody-drug conjugates using Dualitybio’s proprietary DUPAC platform. The partnership is...
Preclinical data – immune-oncology translational signals
Researchers reported preclinical efficacy data for CDX-6114, an oral phenylalanine ammonia lyase in a large-animal phenylketonuria model. Presented at the Society for the Study of Inborn Errors of...
Regulatory and deal watch – anti-drug uncertainties in RNAi space
Alnylam is responding to new competitive pressure after AstraZeneca’s Wainua trial results for ATTR-CM did not meet expectations. In the reporting, some analysts interpreted the miss as evidence...
Access & funding – patient-centered rare disease pathway in China
Glubio Therapeutics’ GLB-005 (a WIZ molecular glue degrader) was added to China’s Center for Drug Evaluation Patient-Centered Action for Rare Diseases Encouragement (CARE) plan. The inclusion...
Dealmaking: Lilly buys immunology asset
Eli Lilly agreed to acquire Merida Biosciences in a deal valued at up to $2.875 billion, marking its 13th acquisition of 2026. The purchase gives Lilly a foothold in therapies aimed at selectively...
Regulatory approval: first-in-class hepcidin mimetic for PV
The FDA cleared Takeda’s U.S. marketing of Mimrylo (rusfertide), a hepcidin mimetic from Protagonist Therapeutics, for adults with polycythemia vera. The decision follows phase 3 clinical data...
Oncology: oral RAS inhibitor wins FDA approval for metastatic PDAC
The FDA approved Revolution Medicines’ oral therapy Rasonque (daraxonrasib), the first RAS inhibitor authorized for the treatment of metastatic pancreatic ductal adenocarcinoma in appropriate...
Clinical pipeline (early oncology signal): BEGONIA platform combination
In the BEGONIA phase 1b/2 trial, durvalumab plus trastuzumab deruxtecan produced unusually deep and durable responses as a first treatment for HER2-low metastatic breast cancer. The study pairs an...
Immunology platform innovation: recyclable LYTACs
Researchers reported macropinocytosis-mediated recyclable LYTACs (McR-TACs), a targeted protein-degradation approach designed to address limitations of earlier LYTAC systems that rely on...
Targeted degradation: AOCs and selective immunology therapeutics
A new analysis highlights how antibody–oligonucleotide conjugates (AOCs) are advancing targeted therapeutics, tracing today’s platform development back to the “magic bullet” concept. The piece...
Biopharma policy and compliance: lobbying spend in Washington
Leading laboratory, diagnostics, and tools companies spent more than $26 million on Washington, D.C. lobbying in the first half of 2026, according to reporting that points to reimbursement and...
AI in clinical operations: oversight and validation gaps
A new report argues that health systems have moved quickly to deploy third-party AI tools while testing and validation infrastructure has not kept pace. The analysis finds that more than 90% of...
Biopharma licensing and late-stage epilepsy asset
SK Biopharmaceuticals secured global rights to opakalim, a Kv7-targeting small molecule in pivotal epilepsy testing, under a licensing deal with Biohaven. Biohaven will receive non-dilutive...
Research funding: NIH grant targets virus-infected cell death biology
A virologist was awarded a $2 million NIH grant to study how virus-infected cells live and die, focusing on cell-death pathways that can determine disease progression and antiviral response. The...
FDA approval – new targeted oral therapy in pancreatic cancer
The FDA approved Revolution Medicines’ oral RAS(ON) inhibitor daraxonrasib (Rasonque) for metastatic pancreatic ductal adenocarcinoma (PDAC) in a new label aimed at patients who received at least...